Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
As the low carbon transition of power systems accelerates, low carbon demand response, characterized by both environmental ...
Although artificial intelligence (AI) has demonstrated potential in automating glaucoma screening, there is still a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results